Find patient medical information for Lutathera (lutetium lu 177 dotatate) on WebMD including its uses, side effects and safety, interactions, pictures, warnings, and user ratings ...

Lutathera and Pluvicto both contain a form of lutetium Lu 177 as the active ingredient. They’re both radiopharmaceuticals, but each is used to treat a different type of cancer.

Lutathera (lutetium Lu 177 dotatate) can cause side effects that range from mild to serious. More common side effects include nausea, vomiting, and fatigue. If side effects become difficult to ...

Lutathera treatment was shown to lower the chance of the tumors getting worse by 79%. At month 20, more than 65% of people who received Lutathera had not progressed, compared to about 11% of ...

Novartis has temporarily stopped producing its neuroendocrine tumor therapy Lutathera as well as its freshly FDA-approved prostate cancer drug Pluvicto at facilities in Ivrea, Italy, and Millburn ...

FRIDAY, Jan. 26, 2018 -- Lutathera, or lutetium Lu 177 dotatate, is the first radioactive drug to be approved by the U.S. Food and Drug Administration to treat certain cancers of the ...

The FDA has approved Lutathera (lutetium Lu 177 dotate) for the treatment of patients with somatostatin receptor—positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The approval is based ...

The approval was based on a Phase 3 study which demonstrated a 79% reduction in the risk of disease progression or death within the Lutathera plus best standard of care arm (octreotide LAR 30mg ...